Difference between revisions of "Trabectedin (Yondelis)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "[http://online.lexi.com/ Lexicomp]" to "Lexicomp")
 
(24 intermediate revisions by 4 users not shown)
Line 1: Line 1:
 
==General information==
 
==General information==
−
Class/mechanism: Binds to the minor groove of DNA, which distorts the DNA helix and its major groove.  This binding interrupts normal cell function and interferes with the expression of several several transcription factors, DNA binding proteins, and DNA repair mechanisms, which interrupts cell cycle and leads to tumor death.<ref name="insert">[http://www.janssen.ca/subcategory_docdownload?id=633 Trabectedin (Yondelis) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/trabectedin.pdf Trabectedin (Yondelis) package insert (locally hosted backup)]</ref>
+
Class/mechanism: Alkylator, binds to the minor groove of DNA, which distorts the DNA helix and its major groove.  This binding interrupts normal cell function and interferes with the expression of several several transcription factors, DNA binding proteins, and DNA repair mechanisms, which interrupts cell cycle and leads to tumor death.<ref name="insert">[https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/YONDELIS-pi.pdf Trabectedin (Yondelis) package insert]</ref><ref>[[:File:Trabectedin.pdf|Trabectedin (Yondelis) package insert (locally hosted backup)]]</ref><ref>[https://www.yondelis.com/ Yondelis manufacturer's website]</ref>
 
<br>Route: IV
 
<br>Route: IV
 
<br>Extravasation: [[vesicant]]
 
<br>Extravasation: [[vesicant]]
  
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
  
 
==Diseases for which it is used==
 
==Diseases for which it is used==
 +
*[[Leiomyosarcoma]]
 +
*[[Liposarcoma]]
 
*[[Ovarian cancer]]
 
*[[Ovarian cancer]]
−
*[[Sarcoma]]
+
*[[Soft tissue sarcoma]]
  
 
==Patient drug information==
 
==Patient drug information==
−
*[http://www.janssen.ca/subcategory_docdownload?id=634 Trabectedin (Yondelis) patient drug information from manufacturer]<ref>[http://www.janssen.ca/subcategory_docdownload?id=634 Trabectedin (Yondelis) patient drug information from manufacturer]</ref>
+
*[https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/YONDELIS-pi.pdf Trabectedin (Yondelis) package insert]<ref name="insert"></ref>
 +
*[https://www.yondelis.com/patient Trabectedin (Yondelis) patient drug information from manufacturer]<ref>[https://www.yondelis.com/patient Trabectedin (Yondelis) patient drug information from manufacturer]</ref>
 +
*[https://chemocare.com/druginfo/trabectedin.aspx Trabectedin (Yondelis) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/trabectedin.aspx Trabectedin (Yondelis) patient drug information (Chemocare)]</ref>
 
*[http://www.uptodate.com/contents/trabectedin-patient-drug-information Trabectedin (Yondelis) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/trabectedin-patient-drug-information Trabectedin (Yondelis) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/trabectedin-patient-drug-information Trabectedin (Yondelis) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/trabectedin-patient-drug-information Trabectedin (Yondelis) patient drug information (UpToDate)]</ref>
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
−
* 9/30/2004: Granted orphan status for treatment of [[Sarcoma | soft tissue sarcoma]].
+
* 2015-10-23: [https://pubmed.ncbi.nlm.nih.gov/28774898/ Approved] for the treatment of patients with unresectable or metastatic [[liposarcoma]] or [[leiomyosarcoma]] who have received a prior [[Regimen_classes#Anthracycline-based_regimen|anthracycline-containing regimen]]. ''(Based on ET743-SAR-3007)''
−
* 3/29/2005: Granted orphan status for treatment of patients with [[Ovarian cancer | ovarian cancer]].
+
==History of changes in EMA indication==
−
* 10/23/2015: FDA approved "for the treatment of patients with unresectable or metastatic [[Sarcoma|liposarcoma or leiomyosarcoma]] who have received a prior [[:Category:Anthracyclines|anthracycline-]]containing regimen"
+
*2007-09-17: Initial authorization
 +
==History of changes in Health Canada indication==
 +
*2010-05-13: Initial notice of compliance
 +
==History of changes in PMDA indication==
 +
*2015-09-28: Initial approval for the treatment of patients with [[soft tissue sarcoma]].
 +
==Also known as==
 +
*'''Code name:''' ET-743
 +
*'''Brand name:''' Yondelis
  
−
==Also known as==
 
−
ecteinascidin 743 or ET-743
 
 
==References==
 
==References==
 
<references/>
 
<references/>
  
−
[[Category:Drug index]]
+
[[Category:Drugs]]
−
[[Category:Chemotherapy]]
+
[[Category:Intravenous medications]]
−
[[Category:Intravenous chemotherapy]]
+
[[Category:Vesicant]]
−
[[Category:Vesicant chemotherapy]]
+
[[Category:Alkylating agents]]
−
[[Category:Orphan drug]]
 
  
 +
[[Category:Leiomyosarcoma medications]]
 +
[[Category:Liposarcoma medications]]
 
[[Category:Ovarian cancer medications]]
 
[[Category:Ovarian cancer medications]]
−
[[Category:Sarcoma medications]]
+
[[Category:Soft tissue sarcoma medications]]
  
−
[[Category:Drugs FDA approved in 2015]]
+
[[Category:EMA approved in 2007]]
 +
[[Category:FDA approved in 2015]]
 +
[[Category:Health Canada approved in 2010]]
 +
[[Category:PMDA approved in 2015]]

Latest revision as of 12:11, 29 June 2024

General information

Class/mechanism: Alkylator, binds to the minor groove of DNA, which distorts the DNA helix and its major groove. This binding interrupts normal cell function and interferes with the expression of several several transcription factors, DNA binding proteins, and DNA repair mechanisms, which interrupts cell cycle and leads to tumor death.[1][2][3]
Route: IV
Extravasation: vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

History of changes in EMA indication

  • 2007-09-17: Initial authorization

History of changes in Health Canada indication

  • 2010-05-13: Initial notice of compliance

History of changes in PMDA indication

Also known as

  • Code name: ET-743
  • Brand name: Yondelis

References

  1. ↑ 1.0 1.1 1.2 Trabectedin (Yondelis) package insert
  2. ↑ Trabectedin (Yondelis) package insert (locally hosted backup)
  3. ↑ Yondelis manufacturer's website
  4. ↑ Trabectedin (Yondelis) patient drug information from manufacturer
  5. ↑ Trabectedin (Yondelis) patient drug information (Chemocare)
  6. ↑ Trabectedin (Yondelis) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Trabectedin_(Yondelis)&oldid=87769"